AGS

AGS

AGS Therapeutics is an early-stage biotechnology company pioneering a novel drug delivery platform using Microalgae Extracellular Vesicles (MEVs) and developing an internal R&D pipeline.

AGS mechanisms move through the body unlike synthetic, animal or human made delivery mechanisms. See slideshow below.

AGS Materials (Copy) (Copy) (Copy) (Copy) (Copy) (Copy)

AGS Materials (Copy) (Copy) (Copy) (Copy) (Copy) (Copy)

AGS Materials (Copy) (Copy) (Copy) (Copy) (Copy) (Copy)

AGS Materials (Copy) (Copy) (Copy) (Copy) (Copy) (Copy)

Direct Investment

Early BioTech - MicroAlgae Delivery Mechanism Opportunity

MEVs (microalgal extracellular vesicles) are the cornerstone of the AGS technology platform, forming the basis for our therapeutic, vaccine, and gene therapy products. Many off ramps for investors.

MEVs are naturally occurring, nanosized lipid-bilayer particles known as extracellular vesicles, derived from unicellular green microalgae like Chlorella. Imagine your body welcomes medicine instead of rejects it, because the delivery mechanism is made of chlorella, an organic material that is healing for the body.

AGS Website

Raising $6M Pre-series A

Screenshot 2025-06-22 at 4.41.59 PM.png

Screenshot 2025-06-22 at 4.42.18 PM.png

Screenshot 2025-06-22 at 4.42.34 PM.png

Screenshot 2025-06-22 at 4.42.49 PM.png

Screenshot 2025-06-22 at 4.44.05 PM.png